



NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1996PLC086581

Date: 14th August 2025

To,
BSE Limited
Department of Corporate Service (DCS-CRD),
Phiroze Jeejeebhoy Towers,
14th Floor, P. J. Tower Dalal Street,
Fort, Mumbai – 400 001.

Sub: Outcome of board meeting held on Thursday, 14th August 2025 pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Ref: NORRIS MEDICINES LIMITED (Scrip Code: 524414).

Dear Sir/Madam,

With reference to above captioned subject, pursuant to Regulation 30 & 33 of Chapter IV read with Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and in continuation to our letter dated 11th August, 2025, regarding intimating the date of Board Meeting of Norris Medicines Limited (“**Company**”), we would like to inform you that the Board of Directors at their Meeting held today i.e. Thursday, 14th August, 2025 inter-alia considered and approved the Un-audited Financial Results along with Limited Review Report for the quarter ended 30th June, 2025.

A copy of the Unaudited Financial Results along with Limited Review Report, in this regard is attached as Annexure A.

We are arranging to publish the said Unaudited Financial Results in newspapers in the format prescribed under Regulation 47 of Listing Regulations. The meeting commenced at 07:00 P.M. and concluded at 07:30 P.M. You are requested to take it on your records.

Thanking you.

Yours Faithfully

For NORRIS MEDICINES LIMITED

Vimal D. Shah
Director
DIN: 01506655

Encl.: As above.

BAHEDIA & ASSOCIATES**Chartered Accountants**SF-68 & 69, Hexzone Arcade, Beside Jayaben Modi Hospital, Valia Road,
GIDC, ANKLESHWAR - 393 002. Office : (M) : 84011 20412**CA. B. L. Bahedia**
(FCA., LL.B., D.T.P., B.Com.)

Mobile No. : +91 98241 36264, 97252 20412

E-mail : bbahedia@yahoo.com/gmail.com

"Limited Review Report"

To,

Board of Directors of NORRIS MEDICINES LIMITED

We have reviewed the accompanying statement of unaudited financial results of NORRIS MEDICINES LIMITED, REGD. OFF 801/P, GIDC ESTATE, ANKLESHWAR-393002, for the period ended 30th June, 2025. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 14/08/2025. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2400 "Engagement to Review Financial Statements", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR, BAHEDIA & ASSOCIATES
CHARTERED ACCOUNTANTS
(FRN-114421W)

(CA. B.L. BAHEDIA)
PROPRIETOR
(M.NO.048066)

UDIN: - 25048066BMILZJ3995

PLACE: ANKLESHWAR
DATE: 14/08/2025

NORRIS MEDICINES LIMITED

Regd Off: 801/P, GIDC Estate, Ankleshwar, 393002, Gujarat.

Phone: 02646-223462 Fax 02646 -250126.

email: contact@norrispharma.com. Website: www.norrispharma.com

CIN No.,124230MH1990PLC058071

Rs. In Lakh

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2025

Sl. No.	Particulars	Quarter Ended 30.06.2025 Unaudited	Quarter Ended 31.03.2025 Audited	Quarter Ended 30.06.2024 Unaudited	Previous accounting year ended 31.03.2025 Audited
1	(a) Revenue from Operations	145.66	272.09	72.49	582.02
	(b) Other Income	2.38	4.53	1.16	6.14
	Total Income From Operations (Net)	148.04	276.62	73.65	588.15
2	Expenses				
	a. Cost of Materials Consumed	103.84	145.46	55.09	337.10
	b. Changes in Inventories of Finished Goods, work in Progress and stock in trade	(31.33)	30.98	(37.83)	8.06
	c. Employee Benfit Expenses	41.17	51.45	34.31	140.72
	d. Finance Costs	11.15	14.55	8.45	43.96
	e. Depreciation and Amortisation Expense	12.25	13.94	13.18	53.70
	f. Other expenditure	42.00	37.15	37.07	122.42
	Total Expenses	179.08	293.53	110.27	705.96
3	Profit/ Loss before Tax (1-2)	-31.04	-16.91	-36.62	-117.81
4	Tax Expense				
	a: Current Tax	0.00	0.00	0.00	0.00
	b: Deferred Tax	0.00	5.94	0.00	5.94
5	Profit / Loss after Tax	-31.04	-22.85	-36.62	-123.75
6	Other Comprehensive Income				
a.	(i) Items that will not be reclassified to profit and loss account	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to Items that will not be reclassified to profit and loss account	0.00	0.00	0.00	0.00
b.	(i) Items that will be reclassified to profit and loss account	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to Items that will be reclassified to profit and loss account	0.00	0.00	0.00	0.00
7	Total Comprehensive Income for the period	-31.04	-22.85	-36.62	-123.75
8	Paid-up equity share capital (Face Value of Rs. 10/- each)	992.58	992.58	992.58	992.58
9	- Basic and diluted	-0.31	-0.23	-0.37	-1.24

Notes:

1) The above Unaudited Fianacial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 14.08.2025. The above results have been subjected to Audit by the Statutory Auditors of the company . .

2) The Financial results of the Company have been prepared with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation,2015 and SEBI circular dated 05.07.2016.

3) The Company is having one segment only and therefore Segmental Reporting is not applicable.

4) There are no exceptional/ extraordinary items during the quarter ended 30.06.2025

5) Previous year/period figures have been regrouped/ rearrangd wherever nessary to make them comperable with current period figures.

For Norris Medicines Limited



Vimal D Shah
Managing Director

Date: 14.08.2025.

Place: Ankleshwar

